NASDAQ:CVAC CureVac (CVAC) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free CVAC Stock Alerts $3.79 +0.12 (+3.27%) (As of 05/29/2024 ET) Add Compare Share Share Today's Range$3.44▼$4.1350-Day Range$2.31▼$3.9752-Week Range$2.21▼$12.36Volume2.26 million shsAverage Volume1.40 million shsMarket Capitalization$848.51 millionP/E RatioN/ADividend YieldN/APrice Target$8.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get CureVac alerts: Email Address CureVac MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside119.9% Upside$8.33 Price TargetShort InterestHealthy3.94% of Float Sold ShortDividend StrengthN/ASustainability-1.88Upright™ Environmental ScoreNews Sentiment0.42Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.11) to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.94 out of 5 starsMedical Sector204th out of 932 stocksPharmaceutical Preparations Industry89th out of 437 stocks 3.0 Analyst's Opinion Consensus RatingCureVac has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageCureVac has only been the subject of 3 research reports in the past 90 days.Read more about CureVac's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.94% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CureVac has recently decreased by 17.54%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCureVac does not currently pay a dividend.Dividend GrowthCureVac does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCureVac has received a 80.57% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "mRNA vaccines" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for CureVac is -1.88. Previous Next 2.5 News and Social Media Coverage News SentimentCureVac has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for CureVac this week, compared to 2 articles on an average week.Search Interest5 people have searched for CVAC on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added CureVac to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CureVac insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.15% of the stock of CureVac is held by insiders.Percentage Held by InstitutionsOnly 17.26% of the stock of CureVac is held by institutions.Read more about CureVac's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CureVac are expected to grow in the coming year, from ($1.11) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CureVac is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CureVac is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCureVac has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CureVac's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About CureVac Stock (NASDAQ:CVAC)CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Read More CVAC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVAC Stock News HeadlinesMay 26, 2024 | finance.yahoo.comCureVac N.V. (NASDAQ:CVAC) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesMay 25, 2024 | finance.yahoo.comCureVac First Quarter 2024 Earnings: Misses ExpectationsMay 24, 2024 | markets.businessinsider.comBuy Rating on CureVac: Positive Financial Outlook and Promising Vaccine Trials Fuel OptimismMay 24, 2024 | seekingalpha.comCureVac: Remains A Hold Based On Bird Flu Vaccine And Oncology AdvancementsMay 23, 2024 | markets.businessinsider.comEQS-News: CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business UpdateMay 23, 2024 | finance.yahoo.comCureVac Announces Financial Results for the First Quarter of 2024 and Provides Business UpdateMay 22, 2024 | msn.comModerna, BioNTech close with double-digit percentage gains amid bird flu fearsMay 22, 2024 | msn.comModerna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., AustraliaMay 10, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Revance Therapeutics (RVNC) and CureVac (CVAC)May 10, 2024 | investorplace.com3 Stocks to Purge ASAP Before They're Pulled off Life SupportMay 10, 2024 | investorplace.com3 Stocks to Purge ASAP Before They're Pulled off Life SupportMay 3, 2024 | finance.yahoo.comSome Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) EstimatesApril 27, 2024 | finance.yahoo.comCureVac Full Year 2023 Earnings: Misses ExpectationsApril 26, 2024 | seekingalpha.comCureVac N.V. (CVAC) Q4 2023 Earnings Call TranscriptApril 26, 2024 | investing.comCureVac appoints new Chief Business OfficerApril 26, 2024 | msn.comLeerink Partners Downgrades CureVac N.V. (CVAC)April 25, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: CureVac (CVAC) and BioMarin Pharmaceutical (BMRN)April 25, 2024 | finance.yahoo.comCureVac N.V. (NASDAQ:CVAC) Q4 2023 Earnings Call TranscriptApril 24, 2024 | markets.businessinsider.comEQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business UpdateApril 24, 2024 | seekingalpha.comCureVac reports Q4 resultsApril 24, 2024 | seekingalpha.comCureVac N.V. 2023 Q4 - Results - Earnings Call PresentationApril 24, 2024 | finanznachrichten.deCureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza ; Development in Collaboration with GSKApril 24, 2024 | msn.comCureVac BV reports Q4 resultsApril 24, 2024 | markets.businessinsider.comEQS-News: CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSKApril 23, 2024 | finance.yahoo.comCureVac N.V. (NASDAQ:CVAC) stock most popular amongst private equity firms who own 31%, while individual investors hold 30%See More Headlines Receive CVAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/24/2024Today5/30/2024Next Earnings (Estimated)8/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CVAC CUSIPN/A CIK1809122 Webwww.curevac.com Phone49-70-71988-30Fax49-7071-9883Employees1,172Year FoundedN/APrice Target and Rating Average Stock Price Target$8.33 High Stock Price Target$13.00 Low Stock Price Target$4.00 Potential Upside/Downside+119.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-281,580,000.00 Net Margins-463.49% Pretax Margin-462.44% Return on Equity-49.22% Return on Assets-33.85% Debt Debt-to-Equity Ratio0.08 Current Ratio2.25 Quick Ratio2.09 Sales & Book Value Annual Sales$58.18 million Price / Sales14.58 Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book1.75Miscellaneous Outstanding Shares223,880,000Free FloatN/AMarket Cap$848.51 million OptionableOptionable Beta2.51 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Alexander Zehnder M.B.A. (Age 54)M.D., CEO, MD & Member of Management Board Comp: $1.05MMr. Pierre Kemula B.Sc. (Age 49)MD, CFO & Member of Management Board Comp: $700.97kDr. Malte Greune Ph.D. (Age 59)COO, Member of Management Board & MD Comp: $643.71kDr. Myriam Mendila M.D. (Age 58)Chief Development Officer, MD & Member of the Management Board Comp: $658.44kDr. Ulrike Gnad-Vogt M.D. (Age 51)Ph.D., Senior VP & Area Head of Oncology Comp: $304.47kDr. Sarah FakihVice President Corporate Communications & Investor RelationsMr. Marco Rau L.L.M.Ph.D., General CounselMr. Thorsten SchullerHead of Corporate CommunicationsSlavica Stevanovic-HeckHead of Human ResourcesDr. Patrick BaumhofSenior Vice President of TechnologyMore ExecutivesKey CompetitorsUltragenyx PharmaceuticalNASDAQ:RAREMerusNASDAQ:MRUSPrestige Consumer HealthcareNYSE:PBHArrowhead PharmaceuticalsNASDAQ:ARWRXenon PharmaceuticalsNASDAQ:XENEView All CompetitorsInstitutional OwnershipRA Capital Management L.P.Sold 778,563 shares on 5/17/2024Ownership: 0.878%Tidal Investments LLCBought 57,625 shares on 5/17/2024Ownership: 0.026%Platinum Investment Management Ltd.Bought 128,778 shares on 5/14/2024Ownership: 0.280%China Universal Asset Management Co. Ltd.Bought 17,132 shares on 4/29/2024Ownership: 0.019%Ballentine Partners LLCBought 12,597 shares on 4/11/2024Ownership: 0.006%View All Institutional Transactions CVAC Stock Analysis - Frequently Asked Questions Should I buy or sell CureVac stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CureVac in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CVAC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVAC, but not buy additional shares or sell existing shares. View CVAC analyst ratings or view top-rated stocks. What is CureVac's stock price target for 2024? 5 brokerages have issued 12 month price targets for CureVac's stock. Their CVAC share price targets range from $4.00 to $13.00. On average, they predict the company's share price to reach $8.33 in the next year. This suggests a possible upside of 119.9% from the stock's current price. View analysts price targets for CVAC or view top-rated stocks among Wall Street analysts. How have CVAC shares performed in 2024? CureVac's stock was trading at $4.21 on January 1st, 2024. Since then, CVAC shares have decreased by 10.0% and is now trading at $3.79. View the best growth stocks for 2024 here. Are investors shorting CureVac? CureVac saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 3,620,000 shares, a drop of 17.5% from the April 30th total of 4,390,000 shares. Based on an average trading volume of 968,600 shares, the days-to-cover ratio is presently 3.7 days. Currently, 3.9% of the company's stock are sold short. View CureVac's Short Interest. When is CureVac's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 15th 2024. View our CVAC earnings forecast. How were CureVac's earnings last quarter? CureVac (NASDAQ:CVAC) announced its quarterly earnings data on Wednesday, April, 24th. The company reported ($0.42) earnings per share for the quarter. The company had revenue of $24.30 million for the quarter. CureVac had a negative trailing twelve-month return on equity of 49.22% and a negative net margin of 463.49%. What ETFs hold CureVac's stock? ETFs with the largest weight of CureVac (NASDAQ:CVAC) stock in their portfolio include Morningstar US Small Growth (MSGR).Amplify Treatments, Testing and Advancements ETF (GERM). What other stocks do shareholders of CureVac own? Based on aggregate information from My MarketBeat watchlists, some companies that other CureVac investors own include Moderna (MRNA), Tesla (TSLA), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Pfizer (PFE), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and NIO (NIO). When did CureVac IPO? CureVac (CVAC) raised $200 million in an initial public offering on Friday, August 14th 2020. The company issued 13,300,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers. Who are CureVac's major shareholders? CureVac's stock is owned by many different institutional and retail investors. Top institutional investors include RA Capital Management L.P. (0.88%), Platinum Investment Management Ltd. (0.28%), Tidal Investments LLC (0.03%), China Universal Asset Management Co. Ltd. (0.02%), Ballentine Partners LLC (0.01%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of CureVac? Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CVAC) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThe 7th Trillion Dollar Company?The Oxford ClubThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport SocietyBUY ALERT: Tiny tech play partners with US governmentStansberry ResearchGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.